In vitro activity of doripenem against Acinetobacter baumannii clinical isolates

Int J Antimicrob Agents. 2009 Feb;33(2):181-2. doi: 10.1016/j.ijantimicag.2008.08.015. Epub 2008 Nov 1.

Abstract

Doripenem is a carbapenem with activity against Gram-positive and Gram-negative pathogens. This study evaluated the in vitro activity of doripenem against a collection of 87 Acinetobacter baumannii clinical isolates, showing that the activity of doripenem was superior to imipenem and meropenem for strains carrying the bla(OXA-58) gene. A. baumannii clinical isolates expressing the bla(OXA-24) gene were resistant to doripenem, imipenem and meropenem. However, in clinical isolates expressing the bla(OXA-58) gene, the percentage of isolates with a doripenem minimum inhibitory concentration >8microg/mL was much lower than that of imipenem and meropenem. This study shows that the activity of doripenem was superior to imipenem and meropenem for strains carrying the bla(OXA-58) gene.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections / microbiology*
  • Acinetobacter baumannii / drug effects*
  • Acinetobacter baumannii / isolation & purification
  • Anti-Bacterial Agents / pharmacology*
  • Carbapenems / pharmacology*
  • Doripenem
  • Humans
  • Imipenem / pharmacology
  • Meropenem
  • Microbial Sensitivity Tests
  • Thienamycins / pharmacology
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Thienamycins
  • Imipenem
  • Doripenem
  • beta-Lactamases
  • beta-lactamase OXA-24
  • beta-lactamase OXA-58, Acinetobacter baumannii
  • Meropenem